Since Transforming Growth Factor β (TGFβ) signaling is commonly disrupted in cancer (Principe et al., 2014) and highly so in pancreatic cancer (Jones et al., 2008), LSL-KrasG12D/+;Tgfbr2flox/flox;Ptf1aCre/+ mice were generated to simultaneously express mutant KrasG12D and loss of the type 2 TGFβ receptor (Tgfbr2) in pancreatic epithelium. This evidence concerns the gene TGFB1 and pancreatic neoplasm.